3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
2
Sarcoma
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
13
Melanoma
5
Lung Neoplasms
3
Breast Neoplasms
3
Sarcoma, Synovial
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Desmoplastic Small Round Cell Tumor
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bone Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma, Endometrial Stromal
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurofibrosarcoma
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Liver Neoplasms
1
Liposarcoma
1
Interventions
Gemcitabine
5
Cisplatin
5
Oxaliplatin
4
pembrolizumab
3
Irinotecan
3
Carboplatin
3
Specimen Handling
2
Radiosurgery
2
Psychiatric Rehabilitation
2
Observation
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Floxuridine
2
Erlotinib Hydrochloride
2
Cyclophosphamide
2
Cetuximab
2
Bortezomib
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tislelizumab
1
spartalizumab
1
sodium thiosulfate
1
selpercatinib
1
rucaparib
1
repotrectinib
1
pidilizumab
1
pazopanib
1
p53 peptide 264-272, human
1
motexafin lutetium
1
montanide ISA 51
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Injections
×
Sarcoma
×
Clear all
NCT05688280
2025-01-08
INJECTABL-1
Immunophotonics, Inc.
Phase 1/2
Active not recruiting
42 enrolled